
Some patients have reported that COVID-19 symptoms recurred after completing treatment and experiencing improvement after Pfizer Inc's (NYSE:PFE) COVID-19 oral antiviral treatment Paxlovid.
Pfizer said that from more than 300,000 patients the company is monitoring who received the 5-day treatment, around 1-in-3,000 - about 0.03% - reported a relapse after taking the pills, Reuters reported